Effectiveness of Two-Dose Zoster Vaccine in Preventing Herpes Zoster Ophthalmicus and Cardiovascular Events
A new study shows that two doses of recombinant zoster vaccine significantly reduce the risk of herpes zoster ophthalmicus and cardiovascular events in adults aged 50 and older, highlighting additional health benefits of vaccination.
A recent study published in Clinical Infectious Diseases has demonstrated that receiving two doses of the recombinant zoster vaccine (RZV) can significantly lower the risk of developing herpes zoster ophthalmicus (HZO), as well as reduce the incidence of acute myocardial infarction and stroke among adults aged 50 and older. The research involved a large cohort analysis conducted by Emily Rayens, Ph.D., M.P.H., from Kaiser Permanente Southern California. The study analyzed data from 102,766 vaccinated individuals and compared outcomes with 411,064 unvaccinated adults, spanning from April 2018 to December 2020.
The findings revealed that vaccinated individuals had a hazard ratio of 0.271 for HZO, indicating a 72.9% effectiveness in preventing this serious complication. Additionally, the risks of hospitalized heart attack and stroke were notably lower in the vaccinated group, with hazard ratios of 0.720 and 0.575 respectively. These results suggest that the benefits of RZV extend beyond its primary purpose of preventing shingles and postherpetic neuralgia, potentially offering broader protection against life-threatening cardiovascular conditions.
Clinicians and public health officials are encouraged to consider these additional advantages when recommending the zoster vaccine for older adults. The study also notes that some authors have disclosed ties to biopharmaceutical companies, including GSK, the manufacturer of RZV.
For more insights, visit the full study: source.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
The Role of GLP-1 Receptor Agonists in Managing Obesity
Explore how GLP-1 receptor agonists like Ozempic are transforming obesity treatment in Australia, highlighting research, clinical applications, and future challenges.
Dormant Stem Cells Provide Insights into Loss and Decline of Sense of Smell
New research reveals that dormant stem cells in the nose actively support the regeneration of olfactory neurons. These findings may lead to therapies for smell loss caused by aging, infections, or neurological diseases.
Advances in Targeted Osteoclast Regulation for Bone Disease Treatment
Innovative research introduces a precision peptide targeting osteoclast signaling, offering new hope for the effective treatment of bone diseases like osteoporosis with fewer side effects.
Long-Term Psychological and Physical Effects of Meningococcal Disease in Adolescents Revealed by Recent Study
Research from the University of Adelaide reveals that nearly 60% of adolescent meningococcal disease survivors experience long-term psychological and physical effects, underscoring the importance of comprehensive post-recovery support.